BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05599984 (ABBV-706 in Advanced Solid Tumors): BVCT ex-ante prediction vs. reported outcome

On 24 Feb 2025, BioinvestGPT's BVCT predicted technical partial failure and commercial failure for this trial. The 1 Jun 2026 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically significant yet commercially insufficient.

Clinical Trial

NCTID
NCT05599984
Drug Name
ABBV-706
Drug MoA
targets SEZ6 with TOP1i payload
Drug Modality
antibody-drug conjugate (ADC)
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Advanced Solid Tumors
Human Patients
288
Sponsor
AbbVie
Phase
Phase 1

Prediction of , index 1941

Prospective Prediction
Prediction Index
1941
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient (additive) clinical benefit in OS inferior to SoC featuring a negative biomarker-response relationship)
Technical Prediction
partial FAILURE (statistically maybe significant yet very weak (additive) clinical benefit in ORR/PFS compared with placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
462 days in advance
Readout Data Interpretation
ABBV-706 achieved 11.3 months mOS for R/R SCLC patients, which are inferior to 13.6 months mOS achieved by the SoC Tarlatamab (see add'l link below)
Press Release
Additional Readout Data
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant yet commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors
Phase
Phase 1
Status
Active not recruiting
Enrollment
288
Lead sponsor
AbbVie
Conditions
Advanced Solid Tumors
Interventions
DRUG: ABBV-706; DRUG: Cisplatin; DRUG: Budigalimab; DRUG: Carboplatin
Design
Non randomized · Sequential · None
Primary purpose
Treatment
Start
2022-12-05
Primary completion
2027-11
Completion
2027-11
Primary outcomes
  • Percentage of Participants With Adverse Events (AE) (Up to Approximately 2 Years)
  • Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706 (Up to Approximately 2 Years)
  • Time to Cmax (Tmax) of ABBV-706 (Up to Approximately 2 Years)
  • Terminal Phase Elimination Half-Life (t1/2) of ABBV-706 (Up to Approximately 2 Years)
  • Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706 (Up to Approximately 2 Years)

NCT05599984 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials